Cubist Systematic Strategies LLC trimmed its holdings in Dermira Inc (NASDAQ:DERM) by 64.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,821 shares of the biopharmaceutical company’s stock after selling 65,030 shares during the period. Cubist Systematic Strategies LLC’s holdings in Dermira were worth $342,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of DERM. Dimensional Fund Advisors LP grew its position in Dermira by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after acquiring an additional 22,816 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in Dermira by 68.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock worth $10,347,000 after acquiring an additional 310,551 shares in the last quarter. GYL Financial Synergies LLC bought a new stake in Dermira in the first quarter worth approximately $288,000. Fox Run Management L.L.C. bought a new stake in Dermira in the second quarter worth approximately $120,000. Finally, Aperio Group LLC grew its position in Dermira by 24.4% in the second quarter. Aperio Group LLC now owns 14,690 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,878 shares in the last quarter. 94.53% of the stock is owned by institutional investors.
Several research firms have commented on DERM. BidaskClub downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Tuesday, October 1st. Zacks Investment Research upgraded shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.36.
Shares of Dermira stock opened at $5.69 on Friday. The firm has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $9.49. The company has a debt-to-equity ratio of 4.95, a quick ratio of 8.08 and a current ratio of 8.42. Dermira Inc has a 1-year low of $5.30 and a 1-year high of $15.48.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.57. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. The business had revenue of $66.65 million during the quarter, compared to analysts’ expectations of $34.16 million. Equities research analysts anticipate that Dermira Inc will post -4.42 earnings per share for the current fiscal year.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira Inc (NASDAQ:DERM).
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.